AlloVir (ALVR) Stock Price, News & Analysis

Company Overview

AlloVir, Inc. (NASDAQ: ALVR) is a clinical-stage biopharmaceutical company specializing in off-the-shelf, memory T-cell therapies to prevent and treat life-threatening viral infections in immunocompromised patients. Founded in 2020 and headquartered in Boston, Massachusetts, AlloVir’s approach leverages a proprietary library of antigen-specific T cells sourced from healthy donors. The company’s platform is designed to address unmet needs in transplant medicine, where viral complications such as cytomegalovirus (CMV), Epstein-Barr virus (EBV) and adenovirus can lead to significant morbidity and mortality.

At the core of AlloVir’s technology is a GMP-compliant manufacturing process that enables rapid identification, enrichment and cryopreservation of virus-specific memory T cells. This allogeneic T-cell library serves as a foundation for both monovalent and multivalent products. The lead candidate, ALVR105, targets CMV in allogeneic hematopoietic stem cell transplant recipients and has advanced into pivotal clinical trials. Additional pipeline programs include therapies against EBV-associated complications and adenoviral infections, reflecting the platform’s versatility.

AlloVir collaborates with academic centers, research institutions and regulatory agencies to optimize trial design and ensure broad access to its therapies. The company has established partnerships in North America and Europe, aiming to secure global supply chains and regulatory approvals. Manufacturing takes place in the United States, with plans for future capacity expansion to support late-stage development and eventual commercialization.

Led by Chief Executive Officer Kenneth Berlin, AlloVir’s management team brings deep expertise in cell therapy, infectious disease and commercial strategy. The company’s board and scientific advisory council include leaders in immunology and transplant medicine, guiding clinical development and regulatory interactions. As AlloVir progresses through pivotal trials, it seeks to offer hospitals and transplant centers a novel therapeutic option for high-risk patients facing viral complications.

Key Stats

• Today's Range: $2.40 to $2.59
• 50-Day Range: $2.36 to $4.30
• 52-Week Range: $7.96 to $24.15
• Volume: 36,951 shs
• Average Volume: 15,383 shs
• Market Capitalization: $12.41 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ALVR Stock Analysis - Frequently Asked Questions

How have ALVR shares performed this year?

AlloVir's stock was trading at $9.66 at the start of the year. Since then, ALVR shares have decreased by 74.5% and is now trading at $2.46.

How were AlloVir's earnings last quarter?

AlloVir, Inc. (NASDAQ:ALVR) issued its quarterly earnings data on Wednesday, August, 14th. The company reported ($1.15) earnings per share for the quarter, beating analysts' consensus estimates of ($2.30) by $1.15.

When did AlloVir's stock split?

AlloVir shares reverse split on the morning of Thursday, January 16th 2025.The 1-23 reverse split was announced on Wednesday, January 15th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, January 15th 2025. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

When did AlloVir IPO?

AlloVir (ALVR) raised $252 million in an initial public offering (IPO) on Thursday, July 30th 2020. The company issued 14,800,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, SVB Leerink and Piper Sandler served as the underwriters for the IPO.

How do I buy shares of AlloVir?

Shares of ALVR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of AlloVir own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AlloVir investors own include Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), AU Optronics (AUOTY), DiamondRock Hospitality (DRH) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 8/14/2024
• Today: 7/17/2025
• Next Earnings (Estimated): 8/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ALVR
• CIK: 1754068
• Web: www.allovir.com
• Phone: 617-433-2605
• Fax: N/A
• Employees: 110
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($20.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$190.42 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -71.03%
• Return on Assets: -61.27%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 86.78
• Quick Ratio: 86.78

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $29.35 per share
• Price / Book: 0.08

Miscellaneous

• Outstanding Shares: 5,043,000
• Free Float: 3,425,000
• Market Cap: $12.10 million
• Optionable: Optionable
• Beta: 0.63